Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2017 Jan 28

PMID 28127569

Citations 10

Authors

Mashael R Al-Anazi

Sabine Matou-Nasri

Ayman A Abdo

Faisal M Sanai

Saad Alkahtani

Saud Alarifi

Abdullah A Alkahtane

Hamad Al-Yahya

Daoud Ali

Mohammed S Alessia

Bushra Alshahrani

Mohammed N Al-Ahdal

Ahmed A Al-Qahtani

Affiliations

Soon will be listed here.

Abstract

Toll-like receptor 3 (TLR3) plays a key role in innate immunity by recognizing pathogenic, double-stranded RNAs. Thus, activation of TLR3 is a major factor in antiviral defense and tumor eradication. Although downregulation of gene expression has been mainly reported in patients infected with hepatitis C virus (HCV), the influence of TLR3 genotype on the risk of HCV infection, HCV-related cirrhosis, and/or hepatocellular carcinoma (HCC) remains to be determined. Single-nucleotide polymorphisms (SNPs) within the gene and their associations with HCV-related disease risk were investigated in a Saudi Arabian population in this study. Eight SNPs were analyzed in 563 patients with HCV, which consisted of 437 patients with chronic HCV infections, 88 with HCV-induced liver cirrhosis, and 38 with HCC. A total of 599 healthy control subjects were recruited to the study. Among the eight SNPs studied, the rs78726532 SNP was strongly associated with HCV infection when compared to that in healthy control subjects. The rs5743314 was also strongly associated with HCV-related liver disease progression (cirrhosis and HCC). In summary, these results indicate that distinct genetic variants of SNPs are associated with HCV infection and HCV-mediated liver disease progression in the Saudi Arabian population.

Citing Articles

TLR3 Gene Polymorphism in HCV Infection in the Kazakh Population of Western Kazakhstan.

Nurlanova G, Zhumagaliyeva G, Iskakova A, Astrakhanov A, Kurmangazin M Asian Pac J Cancer Prev. 2023; 24(11):3925-3930.

PMID: 38019252 PMC: 10772782. DOI: 10.31557/APJCP.2023.24.11.3925.

Enhanced TLR3 responsiveness in hepatitis C virus resistant women from the Irish anti-D cohort.

Sugrue J, Posseme C, Tan Z, Pou C, Charbit B, Bondet V Cell Rep Med. 2022; 3(11):100804.

PMID: 36334594 PMC: 9729829. DOI: 10.1016/j.xcrm.2022.100804.

Association of toll-like receptors single nucleotide polymorphisms with HBV and HCV infection: research status.

Xu Y, Xue W, Gao H, Cui J, Zhao L, You C PeerJ. 2022; 10:e13335.

PMID: 35462764 PMC: 9029363. DOI: 10.7717/peerj.13335.

Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.

Grolmusz V, Bozsik A, Papp J, Patocs A Front Immunol. 2021; 12:653489.

PMID: 33763088 PMC: 7982482. DOI: 10.3389/fimmu.2021.653489.

Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease.

Aslaksen S, Wolff A, Vigeland M, Breivik L, Sheng Y, Oftedal B J Transl Autoimmun. 2020; 1:100005.

PMID: 32743495 PMC: 7388336. DOI: 10.1016/j.jtauto.2019.100005.

References

Assmann T, Brondani L, Bauer A, Canani L, Crispim D . Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. Eur J Endocrinol. 2014; 170(4):519-27. DOI: 10.1530/EJE-13-0963. View

Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X . Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2005; 55(3):403-8. PMC: 1856085. DOI: 10.1136/gut.2005.069153. View

Wang N, Liang Y, Devaraj S, Wang J, Lemon S, Li K . Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol. 2009; 83(19):9824-34. PMC: 2747996. DOI: 10.1128/JVI.01125-09. View

Sironi M, Biasin M, Cagliani R, Forni D, De Luca M, Saulle I . A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J Immunol. 2011; 188(2):818-23. DOI: 10.4049/jimmunol.1102179. View

Keyvani H, Fazlalipour M, Monavari S, Mollaie H . Hepatitis C virus--proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev. 2013; 13(12):5931-49. View

Santos Guedes de Sa K, de Souza Pires-Neto O, Santana B, Gomes S, da Silva Graca Amoras E, da Silva Conde S . Toll-like receptor 3 gene polymorphisms are not associated with the risk of hepatitis B and hepatitis C virus infection. Rev Soc Bras Med Trop. 2015; 48(2):136-42. DOI: 10.1590/0037-8682-0008-2015. View

Kawai T, Akira S . The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373-84. DOI: 10.1038/ni.1863. View

Kim K, Jang B, Chung W, Hwang J, Kweon Y, Tak W . Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis. Korean J Hepatol. 2011; 17(3):220-5. PMC: 3304650. DOI: 10.3350/kjhep.2011.17.3.220. View

Matsumoto M, Funami K, Oshiumi H, Seya T . Toll-like receptor 3: a link between toll-like receptor, interferon and viruses. Microbiol Immunol. 2004; 48(3):147-54. DOI: 10.1111/j.1348-0421.2004.tb03500.x. View

10.

Yin S, Gao B . Toll-like receptor 3 in liver diseases. Gastroenterol Res Pract. 2010; 2010. PMC: 2948910. DOI: 10.1155/2010/750904. View

11.

Guo Z, Chen L, Zhu Y, Zhang Y, He S, Qin J . Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and triggers apoptosis of human hepatocellular carcinoma cells. Oncol Rep. 2011; 27(2):396-402. DOI: 10.3892/or.2011.1538. View

12.

Zarember K, Godowski P . Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002; 168(2):554-61. DOI: 10.4049/jimmunol.168.2.554. View

13.

Huik K, Avi R, Pauskar M, Kallas E, Jogeda E, Karki T . Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infect Genet Evol. 2013; 20:78-82. PMC: 4001117. DOI: 10.1016/j.meegid.2013.08.008. View

14.

Al-Qahtani A, Al-Ahdal M, Abdo A, Sanai F, Al-Anazi M, Khalaf N . Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol. 2012; 84(9):1353-9. DOI: 10.1002/jmv.23271. View

15.

Lin Y, Verma A, Hodgkinson C . Toll-like receptors and human disease: lessons from single nucleotide polymorphisms. Curr Genomics. 2013; 13(8):633-45. PMC: 3492803. DOI: 10.2174/138920212803759712. View

16.

Taura M, Eguma A, Suico M, Shuto T, Koga T, Komatsu K . p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol. 2008; 28(21):6557-67. PMC: 2573237. DOI: 10.1128/MCB.01202-08. View

17.

Halfon P, Munteanu M, Poynard T . FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008; 32(6 Suppl 1):22-39. DOI: 10.1016/S0399-8320(08)73991-5. View

18.

Svensson A, Tunback P, Nordstrom I, Padyukov L, Eriksson K . Polymorphisms in Toll-like receptor 3 confer natural resistance to human herpes simplex virus type 2 infection. J Gen Virol. 2012; 93(Pt 8):1717-1724. DOI: 10.1099/vir.0.042572-0. View

19.

He Q, Graham C, Durante Mangoni E, Koziel M . Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C. Liver Int. 2006; 26(9):1100-10. DOI: 10.1111/j.1478-3231.2006.01357.x. View

20.

Takii Y, Nakamura M, Ito M, Yokoyama T, Komori A, Shimizu-Yoshida Y . Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest. 2005; 85(7):908-20. DOI: 10.1038/labinvest.3700285. View